Compare Danaher Corporation (DHR) vs Global X NASDAQ 100 Covered Call ETF (QYLD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Danaher Corporation vs Global X NASDAQ 100 Covered Call ETF — how do they compare? Danaher Corporation trades at $207.45 (market cap $145.83B), while Global X NASDAQ 100 Covered Call ETF trades at $18.18. The key difference: Danaher Corporation pays a 0.77% dividend while Global X NASDAQ 100 Covered Call ETF pays none, and Global X NASDAQ 100 Covered Call ETF is trading nearer its 52-week high, Danaher Corporation nearer its low. Which is the better fit depends on your goals.
| DHR | QYLD | |
|---|---|---|
Market Cap | $145.83B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $242.05 | $18.52 |
52-Week Low | $161.91 | $16.46 |
Enterprise Value | $168.04B | — |
Dividend Yield | 0.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Danaher (DHR) trades at $209.26, up 2.2% today, with strong technical momentum as the price sits above key support levels. The company has consistently beaten earnings estimates in recent quarters, with Q3 2026 EPS expected at $1.92. Fundamentals show robust profitability with a 58.51% gross margin and 15.95% net income margin, though revenue growth has been modest. Analyst sentiment is overwhelmingly positive with 69% buy ratings and a $202.33 consensus price target. Recent news highlights the acquisition of Masimo and new product launches in its biotechnology segment.
The outlook for DHR remains favorable driven by earnings beats and strategic acquisitions, but investors face risks from elevated valuation multiples and potential macroeconomic headwinds. The stock's current technical overbought condition suggests near-term consolidation may occur, yet long-term growth prospects in life sciences support a bullish stance. Key watch points include Q3 2026 earnings results and integration progress of recent acquisitions.
QYLD trades at $18.18, up 0.17% with a bullish technical signal from moving averages but bearish oscillators. The ETF maintains its covered call strategy, generating consistent monthly dividends, though financial ratios are unavailable. Recent news highlights both the appeal of its 11.67% yield and concerns about long-term underperformance versus the Nasdaq-100.
Outlook: High income potential in sideways markets, but capital appreciation is limited. Risks include erosion of NAV during bull markets and competition from lower-fee alternatives. Suitable for income-focused investors willing to sacrifice growth for yield.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Danaher Corporation
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, including the Fortive separation in 2016, Danaher now focuses primarily on manufacturing scientific instruments and consumables in three segments: life sciences, diagnostics, and environmental and applied solutions. In late 2019, Danaher separated from its dental business through an initial public offering process, and in early 2020, it acquired GE's Biopharma business, now called Cytiva, which added to its life sciences segment.
Read more on DHR →About Global X NASDAQ 100 Covered Call ETF
QYLD is an ETF that follows a covered call strategy on the NASDAQ 100 Index. The fund holds a long position in the stocks of the NASDAQ 100 and simultaneously writes (sells) call options on the index. The primary goal is to generate monthly income from the option premiums. This strategy can reduce portfolio volatility and provide income, but it limits potential capital appreciation from a significant rise in the NASDAQ 100 Index.
Read more on QYLD →
